SCHEMBL6354591

SCHEMBL6354591

NC(=O)c1nn(-c2ccc(S(N)(=O)=O)cc2)c2c1ccc1ccc(NS(=O)(=O)c3cccc(C(F)(F)F)c3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.47
HSD17B2 P37059 1/20 0.46
PTGS2 P35354 6/20 0.44
EPHX2 P34913 5/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
NR3C1 P04150 2/20 0.43
AR P10275 2/20 0.43
GAA P10253 1/20 0.42
PTGS1 P23219 2/20 0.42
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
PTPN2 P17706 2/20 0.41
PTPN1 P18031 2/20 0.41
PTPN5 P54829 2/20 0.41
HSPD1 P10809 1/20 0.41
HSPE1 P61604 1/20 0.41
PDPK1 O15530 1/20 0.41
HIF1A Q16665 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355132 0.92 CA2 (0.42) CA2PTGS2EPHX2PTGS1CCNA2
SCHEMBL6353535 0.87 MAPK1 (0.44) CA2HSD17B2PTGS2HDAC1HDAC8
SCHEMBL6345855 0.87 PTGS2 (0.44) CA2PTGS2PTGS1TSHRPGR
SCHEMBL6352174 0.87 HSD17B2 (0.43) CA2HSD17B2PTGS2PTGS1CCNA2
SCHEMBL6342790 0.87 PTGS2 (0.50) CA2PTGS2EPHX2PTGS1CCNA2
SCHEMBL6352252 0.84 PTGS2 (0.43) CA2PTGS2HDAC1HDAC8PTGS1
SCHEMBL6345751 0.81 CA1 (0.44) CA2PTGS2PTGS1CCNA2CDK2
SCHEMBL6344422 0.80 PTGS2 (0.42) CA2PTGS2PTGS1PDPK1
SCHEMBL6341929 0.79 PTGS2 (0.43) CA2PTGS2PTGS1CCNA2CDK2
SCHEMBL5343100 0.79 IKBKB (0.50) CA2HSD17B2PTGS2EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 CA2 4013/4885HSD17B2 2466/4885PTGS2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.